Search Results for "ATTR-CM"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant External
V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.
Vutrisiran Treatment in Patients with Transthyretin Amyloidosis with Cardiomyopathy
This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.
This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.
Explore ATTR-CM
This slide deck presents of overview of ATTR amyloidosis, covering pathophysiology, disease manifestations and the clinical burden of ATTR-CM.
This slide deck presents of overview of ATTR amyloidosis, covering pathophysiology, disease manifestations and the clinical burden of ATTR-CM.
The ATTR-CM Discovery initiative
Learn more about the ATTR-CM Discovery initiative, A three‑year initiative across 10 US health care centers to develop practical tools and care‑model guidance to strengthen coordination among specialists and clinical teams to improve care pathways and outcomes for patients with ATTR. Alnylam is proud to support the American Heart Association’s ATTR-CM Discovery Initiative.
Learn more about the ATTR-CM Discovery initiative, A three‑year initiative across 10 US health care centers to develop practical tools and care‑model guidance to strengthen coordination among specialists and clinical teams to improve care pathways and outcomes for patients with ATTR. Alnylam is proud to support the American Heart Association’s ATTR-CM Discovery Initiative.
ATTR-CM HELIOS-B Data Summary
ATTR-CM HELIOS-B Data Summary deck provides a comprehensive overview of the HELIOS-B results. Also includes information on ATTR-CM and the MOA of RNAi therapeutics.
ATTR-CM HELIOS-B Data Summary deck provides a comprehensive overview of the HELIOS-B results. Also includes information on ATTR-CM and the MOA of RNAi therapeutics.
RNAi Data Navigator: Focus on Vutrisiran
This interactive PDF provides an overview of ATTR-CM and RNAi therapeutics, and offers a deep dive into the vutrisiran data in ATTR-CM from the HELIOS-B trial, including the primary and additional analyses. Alnylam's ongoing commitment to ATTR amyloidosis is reflected in a summary of the current pipeline and TRITON-CM study design.
This interactive PDF provides an overview of ATTR-CM and RNAi therapeutics, and offers a deep dive into the vutrisiran data in ATTR-CM from the HELIOS-B trial, including the primary and additional analyses. Alnylam's ongoing commitment to ATTR amyloidosis is reflected in a summary of the current pipeline and TRITON-CM study design.
HELIOS-B Plain Language Summary
This material is a short summary of HELIOS-B primary medical and scientific publications (including peer-reviewed medical journal articles and scientific conference presentations)
This material is a short summary of HELIOS-B primary medical and scientific publications (including peer-reviewed medical journal articles and scientific conference presentations)
Phase 3 HELIOS-B Study Rationale
This slide deck highlights the Phase 3 trial design for HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.
This slide deck highlights the Phase 3 trial design for HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.
Vutrisiran: Gastrointestinal Events in HELIOS-B
Standard response letter on vutrisiran and gastrointestinal events in the HELIOS-B study.
Standard response letter on vutrisiran and gastrointestinal events in the HELIOS-B study.
ATTR Amyloidosis Disease State Handout
This handout provides an overview of ATTR manifestations and the diagnostic tools that can be used to assess their presentation.
This handout provides an overview of ATTR manifestations and the diagnostic tools that can be used to assess their presentation.
Vutrisiran: Use in Patients with NYHA Class III and NAC Stage 3, or NYHA Class IV Heart Failure in HELIOS-B
Standard response letter on vutrisiran and patients with NYHA Class III HF and NAC Stage 3 or NHYA Class IV HF.
Standard response letter on vutrisiran and patients with NYHA Class III HF and NAC Stage 3 or NHYA Class IV HF.
Vutrisiran: AL Amyloidosis or Leptomeningeal Amyloidosis
Standard response letter on the use of vutrisiran in patients with AL amyloidosis or leptomeningeal amyloidosis.
Standard response letter on the use of vutrisiran in patients with AL amyloidosis or leptomeningeal amyloidosis.
Vutrisiran: Post-Hoc Analysis of the HELIOS-B Monotherapy Population with Observations Following Tafamidis Initiation Censored
Standard response letter on vutrisiran and a post-hoc analysis of the HELIOS-B monotherapy population censoring data following tafamidis initiation.
Standard response letter on vutrisiran and a post-hoc analysis of the HELIOS-B monotherapy population censoring data following tafamidis initiation.
